RPG Life Sciences Q1FY27: Revenue +15.8%, margin 24.5%

Key takeaway from the June quarter

RPG Life Sciences Limited reported higher revenue and profitability for the quarter ended June 30, 2026 (Q1FY27). Revenue from operations rose 15.8% year-on-year to ₹195.7 crore, compared with ₹168.9 crore in Q1FY26. EBITDA increased 17.9% to ₹48.0 crore from ₹40.7 crore. The EBITDA margin expanded by 40 basis points to 24.5% from 24.1%, indicating tighter operating control during the quarter. Standalone profit after tax (PAT) rose 16.3% to ₹3.057 crore, while consolidated PAT increased 17.0% to ₹3.076 crore.

Board approval and review process

The company said its Board of Directors approved the unaudited standalone and consolidated financial results at a meeting held on July 28, 2026. The results were reviewed by the Audit Committee. They were also subjected to a limited review by statutory auditors S R B C & Co LLP. This process was carried out pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure indicates the numbers are unaudited but reviewed under the applicable listing framework.

Revenue growth led the quarter’s performance

Total income for Q1FY27 increased to ₹199.85 crore from ₹174.15 crore in the prior-year quarter. The step-up in revenue from operations to ₹195.7 crore was the core driver of this improvement. The company’s results note that it delivered profitability growth alongside higher scale, despite what it described as broader market volatility. On an earnings per share basis, standalone basic and diluted EPS rose to ₹18.49 from ₹15.90 in the corresponding quarter of the previous year. Consolidated EPS increased to ₹18.60 from ₹15.90.

Operating profitability improved as margin expanded

EBITDA grew to ₹48.0 crore in Q1FY27, reflecting a faster increase than revenue. The EBITDA margin rose to 24.5% from 24.1%, an expansion of 40 basis points. The company attributed this to improved operating discipline. Margin expansion, even if modest, matters for investors tracking cost control in a quarter where expenses moved up with sales. The quarter’s performance also included the context that there were no exceptional items recorded in Q1FY27.

Other income slipped, while costs rose with revenue

Other income declined to ₹0.416 crore in Q1FY27 from ₹0.523 crore in Q1FY26, which the company linked to lower non-operating receipts. Total expenses rose to ₹158.64 crore from ₹138.72 crore, broadly tracking the revenue increase. Employee benefits expense was reported at ₹0.3776 crore versus ₹0.3370 crore in Q1FY26. Finance costs remained low at ₹0.063 crore for the quarter. The combination of higher operating scale and contained financing costs supported the expansion in operating profit.

Net profit: standalone and consolidated both higher

Standalone PAT increased to ₹3.057 crore from ₹2.63 crore, translating into 16.3% year-on-year growth. Consolidated PAT rose to ₹3.076 crore, up 17.0% year-on-year. The company also pointed out that Q1FY27 had no exceptional items, unlike the previous fiscal year which had impacts related to insurance claims and new labour codes. This contrast is relevant for readers comparing quarterly profitability quality and one-offs.

Snapshot: Q1FY27 versus Q1FY26

The table below summarises the key quarter-on-quarter comparisons disclosed for Q1FY27.

Broader financial context from recent years

The dataset accompanying the update also provides a longer view of operating trends. Annual net sales were shown at ₹653.43 crore for FY25 and ₹707.52 crore for FY26. Over the same period, operating profit was listed at ₹159.0 crore for FY25 and ₹148.01 crore for FY26, while net profit was ₹183.0 crore for FY25 and ₹115.0 crore for FY26. EPS was shown at ₹110.79 for FY25 and ₹69.64 for FY26. These figures help frame Q1FY27’s year-on-year growth against a backdrop where profitability metrics have fluctuated year to year.

Market datapoints cited alongside the results

The information set also includes several trading and market metrics for RPG Life Sciences, including price points such as ₹2,430 and ₹2,401.45, and a stated current share price of ₹2,416.5. Separately, it also notes an instance where the stock fell 5.82% to ₹2,346.90 in early trade on a Monday following results for the quarter ended June 2025. Since these price references span different contexts, investors typically map near-term price moves to the specific reporting period and the market’s expectation gap.

Why the Q1FY27 print matters

For Q1FY27, the key signal is the combination of double-digit revenue growth, EBITDA growth ahead of revenue, and a slightly higher margin. The decline in other income suggests operating performance, rather than non-operating receipts, is the primary contributor to the quarter’s outcome. Low finance costs remain a supportive feature in the reported numbers. And the absence of exceptional items in Q1FY27 reduces noise in interpreting profitability relative to prior periods that included one-offs.

What to watch next

The company has already completed board approval and statutory limited review for Q1FY27 under SEBI’s listing regulations. Investors tracking subsequent quarters will typically monitor whether revenue momentum sustains, whether the 24.5% EBITDA margin holds, and how costs track sales. Another practical monitor is the contribution from non-operating items, given other income declined year-on-year in the latest quarter. Any future disclosures related to further board actions or regulatory filings would provide the next formal set of updates.